Cover Image: October 2005 Scientific American Magazine See Inside

New Bull's-Eyes for Drugs [Preview]

A familiar class of cell-surface receptors turns out to offer an array of fresh targets that could yield new treatments for disorders ranging from HIV infection to obesity















Share on Tumblr

An amazing fraction--roughly half--of all the medicines prescribed today have a striking commonality. At the molecular level, they act on the same type of target: a serpentine protein that weaves seven times through the membrane that envelops the cell. External parts of each serpent serve as an antenna for molecular signals approaching the cell, and internal parts trigger the cell's responses to such cues, beginning with the activation of a signal processor called a G-protein. The serpents themselves are thus known as G-protein coupled receptors, or GPCRs.

As a group, GPCRs show far more versatility than any other class of cell-surface receptor. For instance, the natural molecules to which GPCRs respond range in size from neurotransmitters that are only a few times as massive as a single carbon atom all the way up to proteins 75 times larger than that. Moreover, GPCRs participate in just about every bodily function that sustains life, from heartbeat and digestion to breathing and brain activity. The drugs that target these receptors are equally diverse. The list includes blood pressure reducers (such as propranolol), stomach acid suppressors (such as ranitidine), bronchodilators (such as albuterol) and antidepressants (such as paroxetine). The disorders these medicines treat include hypertension, congestive heart failure, ulcer, asthma, anxiety, allergy, cancer, migraine and Parkinson's disease.


This article was originally published with the title New Bull's-Eyes for Drugs.



Subscribe     Buy This Issue

Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.

Comments

Add Comment
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

New Bull's-Eyes for Drugs: Scientific American Magazine

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X